Cancer cell-based therapies coming into 'important' year for R&D, say SVB analysts
Despite investor doubt in allogeneic cell therapy, 2023 will be an “important” year for both autologous and allogeneic immune-cell-based therapies in multiple myeloma and non-Hodgkin’s lymphoma, SVB analysts predict.
With drug candidates like mosunetuzumab, glofitamab and epcoritamab making their way through clinical trials, SVB Securities analysts are predicting the commercialization of bispecific CD3 T-cell engagers will begin to be a part of treatment paradigms as these drugs get approved.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.